NZ591108A - Dabigatran for percutaneous interventional cardiac catheterisation - Google Patents

Dabigatran for percutaneous interventional cardiac catheterisation

Info

Publication number
NZ591108A
NZ591108A NZ591108A NZ59110809A NZ591108A NZ 591108 A NZ591108 A NZ 591108A NZ 591108 A NZ591108 A NZ 591108A NZ 59110809 A NZ59110809 A NZ 59110809A NZ 591108 A NZ591108 A NZ 591108A
Authority
NZ
New Zealand
Prior art keywords
dabigatran
interventional cardiac
cardiac catheterisation
percutaneous interventional
percutaneous
Prior art date
Application number
NZ591108A
Other languages
English (en)
Inventor
Paul A Reilly
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41258283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ591108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NZ591108A publication Critical patent/NZ591108A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
NZ591108A 2008-08-19 2009-08-17 Dabigatran for percutaneous interventional cardiac catheterisation NZ591108A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9001808P 2008-08-19 2008-08-19
PCT/EP2009/060592 WO2010020602A1 (en) 2008-08-19 2009-08-17 Dabigatran for percutaneous interventional cardiac catheterisation

Publications (1)

Publication Number Publication Date
NZ591108A true NZ591108A (en) 2012-11-30

Family

ID=41258283

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ591108A NZ591108A (en) 2008-08-19 2009-08-17 Dabigatran for percutaneous interventional cardiac catheterisation

Country Status (19)

Country Link
US (1) US20110301201A1 (enExample)
EP (1) EP2328580A1 (enExample)
JP (1) JP2012500245A (enExample)
KR (1) KR20110044230A (enExample)
CN (1) CN102123707A (enExample)
AR (1) AR073077A1 (enExample)
AU (1) AU2009284217A1 (enExample)
BR (1) BRPI0917507A2 (enExample)
CA (1) CA2734794A1 (enExample)
CL (1) CL2011000361A1 (enExample)
CO (1) CO6290686A2 (enExample)
EA (1) EA201100358A1 (enExample)
EC (1) ECSP11010825A (enExample)
IL (1) IL210005A0 (enExample)
MA (1) MA32563B1 (enExample)
MX (1) MX2011001612A (enExample)
NZ (1) NZ591108A (enExample)
TW (1) TW201022235A (enExample)
WO (1) WO2010020602A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102209544A (zh) 2008-11-11 2011-10-05 贝林格尔.英格海姆国际有限公司 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良安全性的方法
CA2791561A1 (en) * 2010-03-01 2011-09-09 Ratiopharm Gmbh Dabigatran etexilate-containing oral pharmaceutical composition
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法
CN103420982B (zh) * 2012-05-24 2015-07-08 天津药物研究院 达比加群酯衍生物及其制备方法和用途
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420985B (zh) * 2012-05-24 2015-09-23 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420984B (zh) * 2012-05-24 2015-07-08 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103524559B (zh) * 2012-07-05 2016-09-28 西藏海思科药业集团股份有限公司 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途
CN103539779B (zh) * 2012-07-13 2016-12-21 四川海思科制药有限公司 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途
US20150225370A1 (en) * 2012-09-28 2015-08-13 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
US9399616B2 (en) * 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
WO2014145986A1 (en) 2013-03-15 2014-09-18 Verseon, Inc. Multisubstituted aromatic compounds as serine protease inhibitors
ES2791749T3 (es) 2013-03-15 2020-11-05 Verseon Corp Halogenopirazoles como inhibidores de la trombina
KR20170048410A (ko) 2014-09-17 2017-05-08 베르선 코포레이션 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물
AU2016224974B2 (en) 2015-02-27 2019-09-26 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
IL280078B2 (en) 2018-07-13 2024-04-01 Verseon Int Corporation Thrombin inhibitors, formulations, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1870100T1 (sl) * 2002-03-07 2012-05-31 Boehringer Ingelheim Int Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline
CA2587026A1 (en) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
AR061996A1 (es) * 2006-07-17 2008-08-10 Boehringer Ingelheim Int Indicaciones para los inhibidores directos de la trombina en el campo cardiovascular
JP2009543844A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 直接トロンビン阻害剤の新しい小児適応症
EP2074112A1 (en) * 2006-10-10 2009-07-01 Boehringer Ingelheim International GmbH Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester

Also Published As

Publication number Publication date
EP2328580A1 (en) 2011-06-08
CO6290686A2 (es) 2011-06-20
WO2010020602A1 (en) 2010-02-25
KR20110044230A (ko) 2011-04-28
MX2011001612A (es) 2011-03-04
BRPI0917507A2 (pt) 2015-11-17
CL2011000361A1 (es) 2011-06-17
MA32563B1 (fr) 2011-08-01
CA2734794A1 (en) 2010-02-25
JP2012500245A (ja) 2012-01-05
TW201022235A (en) 2010-06-16
CN102123707A (zh) 2011-07-13
EA201100358A1 (ru) 2011-10-31
ECSP11010825A (es) 2011-03-31
IL210005A0 (en) 2011-02-28
AR073077A1 (es) 2010-10-13
AU2009284217A1 (en) 2010-02-25
US20110301201A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
CL2011000361A1 (es) Uso de dabigatran para preparar un medicamento util para medicacion secundaria en la cateterizacion cardiaca intervencionista percutanea realizada en conjunto con la implantacion de un stent.
WO2009127973A3 (en) Introducer
WO2010088541A8 (en) Subcutaneous vascular access ports and related systems, methods, and implantation features
NZ720736A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
WO2011088285A3 (en) Apparatus and method for implanting and securing the position of implantable medical device
WO2012135656A3 (en) Intra-luminal access apparatus and methods of using the same
WO2011147407A3 (de) Katheterballon beschichtet mit einem antirestenotischen wirkstoff und einem transportfördernden molekulardispersionsmittel
IL215815A0 (en) Injection catheter for delivering a therapeutic agent into a substrate
IL213325A (en) Use of imidazole derivatives for the preparation of selective activity against infections of the clostridium difficile bacterium or diseases resulting from the clostridium difficile bacterium
WO2013116521A3 (en) Guide extension catheter
EP4424283A3 (en) System and methods for treating a bifurcation with a fully crimped stent
EP2406765A4 (en) DEVICE FOR ADMINISTERING A MEDICAMENT TO A PATIENT WITH RESTRICTED PATIENT-SIDED ACCESS TO THE MEDICAMENT IN THE CASE OF CONTRAINDICATIONS AND APPLICATION METHOD THEREFOR
UA108885C2 (uk) Композиція рисперидону для ін'єкційної депо-форми
DK2387977T5 (da) Katetersystem til indføring af en udvidelig hjerteklapstent i kroppen af en patient
NZ595046A (en) Compositions and methods for extended therapy with aminopyridines
MX2014000777A (es) Cateter, en particular cateter permanente para el tratamiento de disfunciones y/o enfermedades de la vejiga y/o la prostata.
HK1205956A1 (en) Implantable biocompatible tubular material
WO2009103476A8 (en) Antitumoral agents with a benzophenanthridine structure and formulations containing them
GB201010246D0 (en) Stent-Graft
IN2015KN00212A (enExample)
EP2224990A4 (en) CATHETER FOR LOCAL INFUSION OF MEDICINES
WO2013025751A3 (en) Urethral catheter tension holding and movement stabilizing devices
NZ584766A (en) Method, composition, and article of manufacture for providing alpha-1 antitrypsin
PH12014500649A1 (en) Transdermal venous access locking solutions
TN2011000072A1 (en) Dabigatran for percutaneous interventional cardiac catheterisation

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed